# Advanced Breast Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-breast-cancer

> 6 upcoming FDA catalysts in advanced Breast Cancer: Piqray (alpelisib, NVS) on Feb to May 2027 (topline data readout); Piqray (alpelisib, NVS) on February 2027 (primary completion); Etcamah (camizestrant, AZN) on Dec 2027 to Mar 2028 (topline data readout); Etcamah (camizestrant, AZN) on December 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced Breast Cancer | scheduled | "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524000)) |
| February 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced Breast Cancer | scheduled | "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524000)) |
| Dec 2027 to Mar 2028 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT07427394 (Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07427394)) |
| December 2027 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT07427394 (Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07427394)) |
| Dec 2029 to Mar 2030 | [Etcamah (camizestrant) topline data readout](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT06380751 (Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380751)) |
| December 2029 | [Etcamah (camizestrant) primary completion](https://sec-api.dev/pdufa/camizestrant) | AZN | Advanced Breast Cancer | scheduled | "NCT06380751 (Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-18 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06380751)) |

## Drugs

- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib) (NVS)
- [Etcamah (camizestrant)](https://sec-api.dev/pdufa/camizestrant) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-breast-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Advanced Breast Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-breast-cancer

```bibtex
@misc{secapidev_indications_advanced_breast_cancer_20261116,
  title        = {Advanced Breast Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-breast-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_breast_cancer_20261116","title":"Advanced Breast Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-breast-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
